Form 4: Revolution Medicines Executive Sells Shares Under 10b5-1 Trading Plan

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, executed transactions involving the company's stock on October 14, 2024.
• These transactions included the exercise of stock options to acquire 16,666 shares of common stock at a price of $4.09 per share.
• Following the option exercise, Kelsey sold 14,056 shares at a weighted average price of $49.3812 and 2,610 shares at a weighted average price of $50.0775.
• These sales were executed under a pre-arranged 10b5-1 trading plan adopted on March 15, 2024.
• After these transactions, Kelsey directly owns 264,408 shares of Revolution Medicines common stock, which includes 86,400 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The use of a 10b5-1 trading plan suggests a pre-planned and transparent approach to stock transactions, potentially mitigating concerns about insider trading.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 trading plans is a standard practice to avoid insider trading concerns. Investors often monitor these transactions for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a widespread practice among executives in publicly traded companies, including those in the pharmaceutical and biotechnology sectors, such as Amgen, Gilead Sciences, and Biogen.
• The reported weighted average sale prices are within a normal range for stock sales by executives at similar companies.

Stakeholder Impact

• Shareholders may be interested in these transactions as they provide insight into executive compensation and potential alignment of interests.
• The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates